

NOT FOR DISTRIBUTION, PUBLICATION OR TRANSMISSION, DIRECTLY OR INDIRECTLY, INTO OR IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR PUBLICATION MAY BE UNLAWFUL. FURTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

#### O3 Holding GmbH - Publication Annual Financial Statements 2024

BIOGGIO, SWITZERLAND, 26 June 2025 - O3 Holding GmbH (the Company), the holding company of KD Pharma Group, a leading CDMO in pharmaceutical and nutritional lipids, announces that its Annual Financial Statements 2024, due not later than 30 April 2025 under the bond terms for The Company's FRN Senior Secured EUR 180,000,000 bond issue with ISIN NO0013360552 issued on 28 October 2024, and for which the publication was delayed to June 2025, have now been published on the Company's website ([www.kdpharmagroup.com/investor-relations](http://www.kdpharmagroup.com/investor-relations)).

As previously communicated, the delay in the audit process has been the root cause, resulting mainly from the added scope and complexity following the acquisition of DSM-Firmenich's Marine Lipids business in Q4 2024. Meanwhile, the audit process has been completed.

The Company understands that timely access to this information is crucial, and we regret any inconvenience or disruption this delay may have caused.

Now that the 2024 annual accounts have been published, the Q1 Interim Reports 2025 publication can be prepared and will be released shortly.

For further information please contact:

[investor.relations@kdpharmagroup.com](mailto:investor.relations@kdpharmagroup.com)

## About KD Pharma Group

The KD Pharma Group is a CDMO that creates health solutions in the pharmaceutical and nutraceutical space. It is also the worldwide leading producer Omega-3 fatty acids for the pharmaceutical and nutraceutical markets, formulation and encapsulation services, with over 710 employees and a presence in the UK, Norway, Germany, Switzerland, Canada, Peru and the US. The KD Pharma Group employs state-of-the-art technology which is protected by numerous patents. Visit [www.kdpharmagroup.com](http://www.kdpharmagroup.com) to learn more.

## IMPORTANT NOTICE

This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, any securities to any person in the United States of America (the United States), Australia, Canada, Japan or in any jurisdiction to whom or in which such offer or solicitation is unlawful.

The securities referred to herein have not been and will not be registered under U.S. Securities Act of 1933, as amended (the Securities Act) and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons, absent such registration, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There will be no public offer of the securities in the United States.

The offer and sale of the securities referred to herein has not been and will not be registered under the applicable securities laws of Australia, Canada or Japan. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan.

In the United Kingdom, this announcement is only directed at “qualified investors” within the meaning of Regulation (EU) 2017/1129 as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the Order) or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc. (all such persons together being referred to as Relevant Persons)). This announcement must not be acted on, or relied upon, by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

In member states of the European Economic Area the placement of any securities described in this announcement is directed exclusively at persons who are “qualified investors” within the meaning of Regulation (EU) 2017/1129, as amended.

Certain statements in this announcement are forward-looking statements. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. We do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. You should not place any undue reliance on forward-looking statements which speak only as of the date of this announcement.

Any decision to purchase or submit any offer to purchase, sell or subscribe for any of the securities described herein should only be made on the basis of an independent review by a prospective investor of the Company's publicly available information. Neither the Sole Manager nor any of their respective affiliates nor any of its or their respective directors, officers, employees, advisers or agents accepts any liability arising from the use of, or make any representation as to the accuracy or completeness of, this announcement or the Company's publicly available information. The information contained in this announcement is for background purposes only and does not purport to be full or complete. The information contained in this announcement is subject to change in its entirety without notice.